RESEARCH TRIANGLE PARK, N.C., Sept. 1, 2010 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced that executive management will participate in two upcoming healthcare conferences as follows:
- Rodman & Renshaw 12Executive management will present at the Rodman & Renshaw 12th Annual Healthcare Conference, to be held on September 12-15, 2010 at the New York Palace Hotel in New York. Management is scheduled to present an overview of the company and research and development programs on September 13, 2010 at 10:50 a.m. Eastern Time. To listen to the audio web cast of the presentation during or after the event, please visit: . An archive of the presentation will be available for replay for at least 30 days.
- Stifel Nicolaus Annual Healthcare Conference 2010. Executive Management will present at the Stifel Nicolaus Annual Healthcare Conference 2010, to be held September 15-17, 2010 at the Four Seasons Hotel in Boston. Management is scheduled to present an overview of the company and research and development programs on September 16, 2010 at 11:30 a.m. Eastern Time. To listen to the audio web cast of the presentation during or after the event, please visit: . An archive of the presentation will be available for replay for 30 days.
Icagen, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. The Company has a clinical stage program in epilepsy and pain.
The Icagen, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=5735
This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words or phrases "believes," "anticipates," "plans," "expects," "intends," "on track," "potential," and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Risk Factors" in the Company's most recent Annual Report on Form 10-Q, filed with the SEC on August 12, 2010. These risk factors include risks as to the Company's lack of liquidity and substantial doubt about the Company's ability to continue as a "going concern;" the Company's ability to raise additional funding; the Company's history of net losses and how long the Company will be able to operate on its existing capital resources; general economic and financial market conditions; the Company's ability to maintain compliance with NASDAQ's continued listing requirements; whether the Company's product candidates will advance in the clinical trials process; the timing of such clinical trials; whether the results obtained in preliminary studies will be indicative of results obtained in clinical trials; whether the clinical trial results will warrant continued product development; whether and when, if at all, the Company's product candidates, including ICA-105665 and the Company's other lead compounds for epilepsy and pain, will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and if such product candidates receive approval, whether such products will be successfully marketed; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
CONTACT: Icagen, Inc. Richard D. Katz, M.D., EVP, Finance and Corporate Development; Chief Financial Officer (919) 941-5206 firstname.lastname@example.org